SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

3,4601

28-мая-25 12:30:25

15 мин. задержка

Акции

+0,1001

+2,98%

Сегодняшний диапазон

3,3605 - 3,6420

ISIN

N/A

Источник

NASDAQ

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

22 май 2025 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

08 май 2025 03:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

23 апр 2025 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

12 мар 2025 04:30:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

11 мар 2025 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

19 фев 2025 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

06 янв 2025 05:00:01 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

18 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

14 ноя 2024 05:00:01 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

07 ноя 2024 04:30:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

29 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

11 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

01 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 сен 2024 21:05:00 Источник Nasdaq GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12 сен 2024 04:30:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

04 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

14 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

01 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.